Semaglutide Plus — what does the phrase actually mean?

Is "semaglutide plus" a specific product, or something else?

The short answer is: it depends on where you read it. Some private clinics market programmes under a name like "semaglutide plus" to signal that their service bundles the medicine with dietary coaching or monitoring. It is not an MHRA-licensed product name. The licensed UK products containing semaglutide for weight management are Wegovy (the weekly injection) and the Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in Europe.

A common misconception is that "plus" implies a higher dose or a more powerful version of the medicine. It does not. The active molecule is identical. What the phrase can legitimately point to is something the clinical evidence genuinely supports: semaglutide produces its best results when paired with a reduced-calorie diet and increased physical activity. The trial designs were explicit about this. So when a clinic frames their offering as "semaglutide plus lifestyle support", the "plus" reflects how the medicine was studied, not a proprietary formula.

If you are comparing services, the thing worth scrutinising is not the name but the clinical infrastructure around it, who reviews your consultation, how dose changes are managed, and what aftercare looks like between appointments. Our clinical team can walk you through what that looks like at nume.

What does the evidence say about semaglutide used this way?

The STEP 1 trial is the most widely cited source here. Published in the New England Journal of Medicine, it followed adults with obesity (without type 2 diabetes) for 68 weeks. Participants on 2.4 mg semaglutide alongside lifestyle intervention lost an average of about 15% of their body weight, compared with around 2.4% in the placebo group. The lifestyle component in that trial was structured: regular dietary counselling and a defined activity target. Participants who stuck to both saw the strongest results.

The newer OASIS 4 trial, which evaluated the 25 mg oral tablet (the Wegovy tablet maintenance dose), reported average weight loss of around 13.6% over 64 weeks in participants who received the tablet alongside lifestyle changes. Among those who adhered fully to treatment, the figure was approximately 17%, though that fully-adherent figure is important context, not a plain average, and should be understood as such.

What both sets of data confirm is that the medicine works as part of a package, not instead of one. Eating habits, protein intake, hydration and strength activity all remain relevant on treatment. More detail on how semaglutide works and what to expect across the dose schedule is worth reading before you start.

Does the Wegovy injection differ from the Wegovy tablet when used "plus" lifestyle support?

The molecule is semaglutide in both cases. The delivery mechanism and dosing schedule differ, which matters practically. The injection is once weekly, starting at 0.25 mg and titrated by the prescriber up to 2.4 mg (and now up to 7.2 mg following MHRA approval in January 2026 of that higher dose). The tablet is once daily, taken first thing in the morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before food or other medicines. Its maintenance dose is 25 mg.

The tablet requires no refrigeration, which some people find genuinely liberating, particularly if they travel frequently or feel uneasy about self-injection. The injection, for its part, has a longer evidence base and is the formulation that NICE has appraised. If you are trying to find the best value Wegovy available in the UK, details on how the two compare in practice, including cost context, are covered on the Wegovy pricing page.

Side effects share a broadly similar profile across both formulations: nausea, loose stools, constipation and fatigue are most common, particularly at the start of treatment or after a dose increase. They typically settle within a week or two for most people. If you want to explore the injection programme specifically, our Ascend Plus semaglutide programme page sets out what that journey looks like step by step.

Who can access semaglutide for weight management, and through which route?

On the NHS, access to Wegovy is via specialist weight management services under NICE technology appraisal TA875, with fairly strict criteria around BMI and comorbidities, and waiting lists that vary widely by area. Tirzepatide (Mounjaro) has a broader phased NHS rollout under NICE TA1026, but the same access pressures apply.

Privately, the eligibility criteria follow the licensed indications: adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI is a starting point, not the whole picture; a prescriber also considers your medical history, current medications and whether this is the right treatment for you specifically. If you are starting at the semaglutide 1 mg dose, understanding what to expect at that stage can help you prepare for the titration ahead.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. That review happens the same day. If you are approved and place your order before 12pm on a working day, your treatment is dispatched that afternoon and delivered free by DPD the next working day, in plain packaging. There are no subscriptions and no hidden costs; every repeat order goes through fresh clinical review. You can verify our pharmacy on the GPhC register using registration number 9012878.

If you are weighing up your options, the weight loss treatment overview covers the full picture of what is currently available and licensed in the UK. When you are ready to take the next step, speak to our prescribers through a free consultation.